Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketamine + magnesium sulfate is a drug combination that leverages the synergistic effects of both compounds on NMDA receptors. Ketamine is a non-competitive NMDA receptor antagonist, while magnesium sulfate is an endogenous voltage-dependent NMDA receptor-channel blocker[1][4]. This combination has been studied for various pain conditions, including neuropathic pain, postoperative pain, and refractory headaches[1][3]. The synergistic interaction occurs because ketamine and magnesium sulfate act on different sites of the NMDA receptor channel[1][4]. This combination may enhance analgesic efficacy while potentially allowing for reduced ketamine dosage, which could minimize adverse effects[1]. Studies have shown that the combination provides better pain control and reduces opioid consumption compared to ketamine alone in various surgical settings[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketamine + magnesium sulfate.